A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer

Go Back to All Clinical Trials

A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Non-small Cell Lung Cancer (nsclc)
Age: Between 18 - 100 Years
Gender: Male or Female

Other Inclusion Criteria:

1) Pathologically confirmed, definitively diagnosed, metastatic NSCLC harboring an activating EGFR mutation. 2) Previously received at least 1 prior EGFR-targeted TKI. 3) EGFR mutation profile determined locally via a Sponsor-approved testing methodology, using either tumor tissue (ideally from a progressing lesion) and/or ctDNA in plasma.

You may not be eligible for this study if the following are true:

1) Tumor harbors any additional known primary driver alterations including but not limited to pathologic abnormalities of EGFR exon 20, KRAS, BRAF V600E, NTRK1/2/3, HER2, ALK, ROS1, MET, or RET. 2) NSCLC with mixed squamous cell histology. 3) Central Nervous System (CNS) metastases or spinal cord compression that is associated with progressive neurological symptoms or requires increasing doses of corticosteroids to control the CNS disease.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies